Aptorum Group Ltd Class A Cash Flow Conversion Efficiency
Aptorum Group Ltd Class A cash flow conversion efficiency. Based on the latest financial reports, Aptorum Group Ltd Class A (APM) has a cash flow conversion efficiency ratio of -0.132x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.64 Million) by net assets ($12.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aptorum Group Ltd Class A (2016–2025)
Cash flow conversion efficiency of Aptorum Group Ltd Class A from 2016 to 2025. This chart illustrates how Aptorum Group Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View APM stock price for real-time trading data and today's change.
Aptorum Group Ltd Class A Cash Flow Conversion Ratio Explained
Aptorum Group Ltd Class A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aptorum Group Ltd Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aptorum Group Ltd Class A ranked by their cash flow conversion efficiency. Also see APM company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ireka Corporation Bhd
KLSE:8834
|
0.003x |
|
MEDICOX Co. Ltd
KQ:054180
|
-0.040x |
|
Oxbridge Re Holdings Equity Warrant
NASDAQ:OXBRW
|
0.067x |
|
Schroder British Opportunities Trus
LSE:SBO
|
-0.007x |
|
Founder Group Limited Ordinary Shares
NASDAQ:FGL
|
-0.841x |
|
Ecoclime Group AB Series B
ST:ECC-B
|
0.000x |
|
BRAXIA SCIENTIFIC CORP.
F:4960
|
N/A |
|
Goldflare Exploration Inc
V:GOFL
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Aptorum Group Ltd Class A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Aptorum Group Ltd Class A from 2016 to 2025. Review Aptorum Group Ltd Class A (APM) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.79 Million | $-1.84 Million | -0.133x | -31.63% |
| 2024-12-31 | $11.78 Million | $-1.19 Million | -0.101x | +79.86% |
| 2023-12-31 | $15.38 Million | $-7.72 Million | -0.502x | +68.07% |
| 2022-12-31 | $7.83 Million | $-12.32 Million | -1.573x | -87.90% |
| 2021-12-31 | $17.51 Million | $-14.65 Million | -0.837x | -100.42% |
| 2020-12-31 | $38.15 Million | $-15.93 Million | -0.418x | +53.66% |
| 2019-12-31 | $14.85 Million | $-13.38 Million | -0.901x | -194.02% |
| 2018-12-31 | $32.75 Million | $-10.04 Million | -0.306x | -60.21% |
| 2017-12-31 | $30.23 Million | $-5.78 Million | -0.191x | -74.34% |
| 2016-12-31 | $25.11 Million | $-2.76 Million | -0.110x | -- |
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more